PPARD and Obesity: The study of PPARβ/δ agonists demonstrates their role in obesity and IR diseases, such as hepatic ischemia/reperfusion injury through NF-κβ pathway inhibition, lipid adipocyte accumulation, and diabetic osteoporosis.